Expression of HER/erbb family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells

Five human rhabdomyosarcoma cell lines were used to investigate the surface expression of HER/erbB receptors, particularly of HER‐2, HER‐3 and HER‐4, by flow cytometry. HER‐2 was expressed in 3/5 rhabdomyosarcoma cell lines. HER‐3 was expressed in all rhabdomyosarcoma cell lines. None of the rhabdomyosarcoma cell lines investigated showed HER‐4 surface expression. To study the biological activity of HER/erbB receptors in rhabdomyosarcomas, cells were cultured in the presence of glial growth factor 2 (GGF‐2), a specific ligand of HER‐3 that is able to stimulate myogenesis in normal myoblasts. In 3 of 3 human rhabdomyosarcoma cell lines positive for both HER‐2 and HER‐3 receptors, the treatment with GGF‐2 induced a significant increase in myogenic differentiation. Int. J. Cancer 87:29–36, 2000. © 2000 Wiley‐Liss, Inc.

[1]  E. Nishida,et al.  Two co‐existing mechanisms for nuclear import of MAP kinase: passive diffusion of a monomer and active transport of a dimer , 1999, The EMBO journal.

[2]  R. Bast,et al.  Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  H. Arnold,et al.  Muscle differentiation: more complexity to the network of myogenic regulators. , 1998, Current opinion in genetics & development.

[4]  A. Afify,et al.  Fluorescent in situ Hybridization Detection of HER-2/neu Gene Amplification in Rhabdomyosarcoma , 1998, Pathobiology.

[5]  I. Pastan,et al.  Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H. Tideman.  ERbB-2 expression is correlated with poor prognosis for patients with osteosarcoma , 1998 .

[7]  H. Müller-Hermelink,et al.  The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. , 1998, The American journal of pathology.

[8]  Michael Sasner,et al.  Neuregulin-β induces expression of an NMDA-receptor subunit , 1997, Nature.

[9]  M. Barinaga.  From Bench Top to Bedside , 1997, Science.

[10]  F. Maurer,et al.  Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. , 1997, Cancer research.

[11]  R H Perry,et al.  Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.

[12]  G. Fischbach,et al.  Maintenance of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. , 1997, Science.

[13]  M. Kim,et al.  An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2 , 1997, Gene Therapy.

[14]  J. Changeux,et al.  Heregulin‐stimulated acetylcholine receptor gene expression in muscle: requirement for MAP kinase and evidence for a parallel inhibitory pathway independent of electrical activity , 1997, The EMBO journal.

[15]  M. Melhem,et al.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[16]  Y. Yarden,et al.  A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.

[17]  P. Lollini,et al.  Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. , 1996, Cancer research.

[18]  R. Lupu,et al.  Involvement of Heregulin-β2 in the Acquisition of the Hormone-independent Phenotype of Breast Cancer Cells , 1996 .

[19]  R. Sklar,et al.  Stimulation of Myogenic Differentiation by a Neuregulin, Glial Growth Factor 2 , 1996, The Journal of Biological Chemistry.

[20]  H. Horiuchi,et al.  ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma , 1996, Cancer.

[21]  S. Frisch,et al.  Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. , 1995, Cancer research.

[22]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[23]  M. Marchionni.  neu tack on neuregulin , 1995, Nature.

[24]  P. Lollini,et al.  Redundancy of autocrine loops in human rhabdomyosarcoma cells: induction of differentiation by suramin. , 1995, British Journal of Cancer.

[25]  K. Sano,et al.  Expression of c-ErbB2 in human neuroblastoma tissues, adrenal medulla adjacent to tumor, and developing mouse neural crest cells. , 1995, The American journal of pathology.

[26]  S. Jo,et al.  Neuregulins are concentrated at nerve-muscle synapses and activate ACh–receptor gene expression , 1995, Nature.

[27]  W. Grizzle,et al.  Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[28]  R. Hesketh.  The Oncogene handbook , 1994 .

[29]  H. Modjtahedi,et al.  Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. , 1994, Invasion & metastasis.

[30]  J. Downing,et al.  Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. , 1993, Cancer research.

[31]  L. Meisner,et al.  Detection of aneuploidy and possible deletion in paraffin-embedded rhabdomyosarcoma cells with FISH. , 1993, Cancer genetics and cytogenetics.

[32]  M. Waterfield,et al.  Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system , 1993, Nature.

[33]  P. Swanson,et al.  Overexpression of the c-erbB-2 oncogene in sarcomas and small round-cell tumors of childhood. An immunohistochemical investigation. , 1992, Archives of pathology & laboratory medicine.

[34]  D. Goeddel,et al.  Identification of Heregulin, a Specific Activator of p185erbB2 , 1992, Science.

[35]  P. Lollini,et al.  Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination. , 1992, British Journal of Cancer.

[36]  M. Campiglio,et al.  Selection of monoclonal antibodies which induce internalization and phosphorylation of P185HER2 and growth inhibition of cells with HER2/neu gene amplification , 1991, International journal of cancer.

[37]  P. Lollini,et al.  Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. , 1991, Invasion & metastasis.

[38]  M. Hung,et al.  Direct sequencing analysis of transmembrane region of human neu gene by polymerase chain reaction , 2006, Molecular carcinogenesis.

[39]  P. Lollini,et al.  Metastatic ability and differentiative properties of a new cell line of human embryonal rhabdomyosarcoma (CCA). , 1989, Anticancer research.

[40]  P. Lollini,et al.  Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. , 1989, Cancer research.

[41]  P. Lollini,et al.  RMZ: a new cell line from a human alveolar rhabdomyosarcoma. In vitro expression of embryonic myosin. , 1986, British Journal of Cancer.

[42]  S. Schiaffino,et al.  Embryonic myosin heavy chain as a differentiation marker of developing human skeletal muscle and rhabdomyosarcoma. A monoclonal antibody study. , 1986, Experimental cell research.